<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01084174</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00032256</org_study_id>
    <nct_id>NCT01084174</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the safety and efficacy of a sublingual (under the
      tongue) immunotherapy (SLIT) dosing regimen and an oral immunotherapy (OIT) regimen in
      inducing desensitization and long term tolerance in children with persistent peanut allergy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To effectively address the Primary Objectives of this pilot study, 30 subjects aged 6-21
      years with: (1) a convincing clinical history of peanut allergy (PA), (2) a serum
      immunoglobulin E (IgE) specific to peanut of &gt;0.35 kilo units per liter (kU/L) and a skin
      prick test (SPT) wheal &gt;3 mm, will be enrolled. Subjects will be recruited from the Johns
      Hopkins Pediatric Allergy Clinic.

      Participants will undergo an initial screening visit that will include a medical history,
      physical exam, skin testing, and phlebotomy. Informed consent and assent will be obtained. At
      the next two visits, 20 participants will complete a double-blind placebo-controlled food
      challenge (DBPCFC). Eligible subjects will be randomized in a 1:1 ratio into two groups. One
      group will receive active SLIT with placebo OIT and the other group will begin active OIT
      with placebo SLIT dose escalation. Over the next 16 weeks of the study, subjects will undergo
      SLIT and OIT dose increases. A maintenance dose will then be taken at home daily for 12
      months. A DBPCFC will be completed after 6 months and 12 months of home dosing. Those
      patients who pass the DBPCFC will be taken off SLIT and OIT for 4 weeks. A final challenge
      will be administered at the end of this period.

      Ten additional peanut-allergic subjects age 6-21 years will be enrolled and followed as
      longitudinal controls for the mechanistic studies. These subjects will follow a modified
      schedule compared to those subjects receiving study treatment and will be evaluated by
      phlebotomy, end point titration prick skin testing, and saliva collection. These patients
      will continue strict avoidance of peanut unless otherwise advised by their personal
      physician.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Induced Peanut Desensitization at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Peanut desensitization was defined as a greater than 10-fold increase in oral food challenge (OFC) threshold after 12 months of therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Between Arm Change in IgG4 From Baseline to End of Dose Build-up (up to 16 Weeks)</measure>
    <time_frame>Baseline and end of dose build-up (up to 16 weeks)</time_frame>
    <description>Serum immunoglobulin G4 (IgG4) levels are measured in milligrams of Antibody per liter (mga/L) and were collected at baseline and at the end of dose build-up (up to 16 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between Arm Change in IgG4 From Baseline to 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>IgG4 levels are measured in milligrams of Antibody per liter (mga/L) and were collected at baseline and at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between Arm Change in IgG4 From Baseline to 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>IgG4 levels are measured in milligrams of Antibody per liter (mga/L) and were collected at baseline and at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between Arm Change in IgE From Baseline to End of Dose Build-up (up to 16 Weeks)</measure>
    <time_frame>Baseline to end of dose build-up (up to 16 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between Arm Change in IgE From Baseline to 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Serum immunoglobulin E (IgE) levels are measured in kilo units of Antibody per liter (kUa/L) and were collected at baseline and at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between Arm Change in IgE From Baseline to 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>IgE levels are measured in kilo units of Antibody per liter (kUa/L) and were collected at baseline and at 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Peanut Hypersensitivity</condition>
  <condition>Food Hypersensitivity</condition>
  <condition>Immediate Hypersensitivity</condition>
  <arm_group>
    <arm_group_label>Active SLIT/Placebo OIT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These subjects will receive peanut powder given orally and placebo extract given sublingually.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active OIT/Placebo SLIT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These subjects will receive peanut extract given sublingually and placebo powder given orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peanut powder</intervention_name>
    <description>Delivered orally</description>
    <arm_group_label>Active SLIT/Placebo OIT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peanut extract</intervention_name>
    <description>Delivered sublingually</description>
    <arm_group_label>Active OIT/Placebo SLIT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo extract</intervention_name>
    <description>Delivered sublingually</description>
    <arm_group_label>Active SLIT/Placebo OIT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo powder</intervention_name>
    <description>Delivered orally</description>
    <arm_group_label>Active OIT/Placebo SLIT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are ages 6 to 21 years of either sex, any race, and any ethnicity at the time of the
             initial visit.

          -  Have a physician diagnosed peanut allergy or a convincing clinical history of peanut
             allergy (urticaria, upper or lower respiratory symptoms, GI disturbances, rash or oral
             symptoms).

          -  Have a skin prick test positive to peanut (diameter of wheal 3 mm ≥ negative control)
             and detectable serum peanut-specific IgE level (UniCAP ≥ 0.35 kU/L).

          -  Have a positive reaction to a cumulative dose of ≤1,000 mg of peanut powder in the
             initial qualifying DBPCFC.

          -  Use an effective method of contraception by females of childbearing potential to
             prevent pregnancy and agree to continue to practice an acceptable method of
             contraception for the duration of their participation in the study.

          -  Ability to perform spirometry maneuvers in accordance with the American Thoracic
             Society (ATS) guidelines (1994).

          -  Have self-injectable epinephrine (i.e. EpiPen® or EpiPen Jr.®) available at all times.

          -  Provide signed informed consent (by parent or legal guardian if the subject is a
             minor) and informed assent if applicable.

        Exclusion Criteria:

          -  Have a history of severe anaphylaxis to peanut with hypoxia (cyanosis or peripheral
             capillary oxygen saturation (SpO2) ≤92% at any stage), hypotension or neurological
             compromise (confusion, collapse, loss of consciousness or incontinence).

          -  Tolerates more than 1,000 mg of peanut powder at the initial qualifying DBPCFC.

          -  Have a viral upper respiratory infection (URI) or gastroenteritis within 7 days of OFC
             (OFC will need to be rescheduled).

          -  Currently participating in a study using an investigational new drug.

          -  Participation in any interventional study for the treatment of food allergy in the
             past 12 months.

          -  Pregnancy or lactation

          -  Allergy to placebo ingredients (Glycerin or oat flour) OR reacts to any dose of
             placebo during the qualifying OFC.

          -  Currently in a buildup phase of any allergy immunotherapy.

          -  Poor control of atopic dermatitis.

          -  Have pulmonary function tests with forced expiratory volume 1 (FEV1) value &lt;80%
             predicted or any clinical features of greater than moderate persistent asthma and
             greater than high daily doses of inhaled corticosteroids (&gt;500µg/day fluticasone or
             equivalent).

          -  Use of steroid medications (oral steroids, such as prednisone or Medrol, steroid
             injections, such as Kenalog, or IV or oral corticosteroid burst) in the following
             manners:

             o History of daily oral steroid dosing within 4 weeks prior to baseline visit or for &gt;
             1 month during the past year or burst oral steroid course in the past 6 months or &gt; 1
             burst oral steroid course in the past year.

          -  Asthma requiring

               -  ≥1 hospitalization in the past year for asthma or

               -  &gt;1 ER visit in the past 6 months for asthma

          -  Use of omalizumab or other non-traditional forms of allergen immunotherapy (e.g., oral
             or sublingual) or immuno-modulatory therapy (not including corticosteroids) or
             biologic therapy within the past year.

          -  Use of β-blockers (oral), angiotensin-converting enzyme (ACE) inhibitors,
             angiotensin-receptor blockers (ARB), calcium channel blockers or tricyclic
             antidepressant therapy.

          -  Inability to discontinue antihistamines for 5 days for long acting and 3 days for
             short acting prior to skin testing or OFC's.

          -  History of alcohol or drug abuse.

          -  Active eosinophilic gastrointestinal disease in the past two years.

          -  Have other significant medical conditions (e.g., liver, gastrointestinal, kidney,
             cardiovascular, pulmonary disease, or blood disorders) which, in the opinion of the
             Investigator, make the subject unsuitable for induction of food reactions.

          -  Any previous intubation due to allergies or asthma.

          -  Severe reaction at initial DBPCFC, defined as:

               -  Life-threatening anaphylaxis

               -  Requiring overnight hospitalization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Wood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-3923</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, Gorelik M, Schroeder J, Hamilton RG, Wood RA. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol. 2015 May;135(5):1275-82.e1-6. doi: 10.1016/j.jaci.2014.11.005. Epub 2014 Dec 18.</citation>
    <PMID>25528358</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2010</study_first_submitted>
  <study_first_submitted_qc>March 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2010</study_first_posted>
  <results_first_submitted>February 23, 2017</results_first_submitted>
  <results_first_submitted_qc>February 23, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 7, 2017</results_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peanut Allergy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Peanut Hypersensitivity</mesh_term>
    <mesh_term>Food Hypersensitivity</mesh_term>
    <mesh_term>Hypersensitivity, Immediate</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active SLIT/Placebo OIT</title>
          <description>These subjects will receive peanut powder given orally and placebo extract given sublingually.
Peanut powder: Delivered orally
Placebo extract: Delivered sublingually</description>
        </group>
        <group group_id="P2">
          <title>Active OIT/Placebo SLIT</title>
          <description>These subjects will receive peanut extract given sublingually and placebo powder given orally.
Peanut extract: Delivered sublingually
Placebo powder: Delivered orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>gastrointestinal symptoms</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Eosinophilic esophagitis</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Anaphylaxis</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active SLIT/Placebo OIT</title>
          <description>These subjects will receive peanut powder given orally and placebo extract given sublingually.
Peanut powder: Delivered orally
Placebo extract: Delivered sublingually</description>
        </group>
        <group group_id="B2">
          <title>Active OIT/Placebo SLIT</title>
          <description>These subjects will receive peanut extract given sublingually and placebo powder given orally.
Peanut extract: Delivered sublingually
Placebo powder: Delivered orally</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior history of peanut anaphylaxis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Other food allergies</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Atopic dermatitis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Induced Peanut Desensitization at 12 Months</title>
        <description>Peanut desensitization was defined as a greater than 10-fold increase in oral food challenge (OFC) threshold after 12 months of therapy.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active SLIT/Placebo OIT</title>
            <description>These subjects will receive peanut powder given orally and placebo extract given sublingually.
Peanut powder: Delivered orally
Placebo extract: Delivered sublingually</description>
          </group>
          <group group_id="O2">
            <title>Active OIT/Placebo SLIT</title>
            <description>These subjects will receive peanut extract given sublingually and placebo powder given orally.
Peanut extract: Delivered sublingually
Placebo powder: Delivered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Induced Peanut Desensitization at 12 Months</title>
          <description>Peanut desensitization was defined as a greater than 10-fold increase in oral food challenge (OFC) threshold after 12 months of therapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Between Arm Change in IgG4 From Baseline to End of Dose Build-up (up to 16 Weeks)</title>
        <description>Serum immunoglobulin G4 (IgG4) levels are measured in milligrams of Antibody per liter (mga/L) and were collected at baseline and at the end of dose build-up (up to 16 weeks)</description>
        <time_frame>Baseline and end of dose build-up (up to 16 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active SLIT/Placebo OIT</title>
            <description>These subjects will receive peanut powder given orally and placebo extract given sublingually.
Peanut powder: Delivered orally
Placebo extract: Delivered sublingually</description>
          </group>
          <group group_id="O2">
            <title>Active OIT/Placebo SLIT</title>
            <description>These subjects will receive peanut extract given sublingually and placebo powder given orally.
Peanut extract: Delivered sublingually
Placebo powder: Delivered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Between Arm Change in IgG4 From Baseline to End of Dose Build-up (up to 16 Weeks)</title>
          <description>Serum immunoglobulin G4 (IgG4) levels are measured in milligrams of Antibody per liter (mga/L) and were collected at baseline and at the end of dose build-up (up to 16 weeks)</description>
          <units>mga/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.19" upper_limit="1.76"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.22" upper_limit="5.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of dose build-up (up to 16 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0.47" upper_limit="7.07"/>
                    <measurement group_id="O2" value="11.3" lower_limit="0.99" upper_limit="58.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.003</p_value>
            <method>Regression, Linear</method>
            <method_desc>Analyzed by linear regression models using generalized estimating equations to account for repeated measures over time with robust standard errors</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Between Arm Change in IgG4 From Baseline to 6 Months</title>
        <description>IgG4 levels are measured in milligrams of Antibody per liter (mga/L) and were collected at baseline and at 6 months</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>One participant in the Active sublingual immunotherapy (SLIT)/Placebo oral immunotherapy (OIT) arm and 4 participants in the Active OIT/Placebo SLIT arm discontinued prior to month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Active SLIT/Placebo OIT</title>
            <description>These subjects will receive peanut powder given orally and placebo extract given sublingually.
Peanut powder: Delivered orally
Placebo extract: Delivered sublingually</description>
          </group>
          <group group_id="O2">
            <title>Active OIT/Placebo SLIT</title>
            <description>These subjects will receive peanut extract given sublingually and placebo powder given orally.
Peanut extract: Delivered sublingually
Placebo powder: Delivered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Between Arm Change in IgG4 From Baseline to 6 Months</title>
          <description>IgG4 levels are measured in milligrams of Antibody per liter (mga/L) and were collected at baseline and at 6 months</description>
          <population>One participant in the Active sublingual immunotherapy (SLIT)/Placebo oral immunotherapy (OIT) arm and 4 participants in the Active OIT/Placebo SLIT arm discontinued prior to month 6.</population>
          <units>mga/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.19" upper_limit="1.76"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.22" upper_limit="5.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="1.51" upper_limit="76.2"/>
                    <measurement group_id="O2" value="83.4" lower_limit="21.2" upper_limit="677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Between Arm Change in IgG4 From Baseline to 12 Months</title>
        <description>IgG4 levels are measured in milligrams of Antibody per liter (mga/L) and were collected at baseline and at 12 months</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>One participant in the Active SLIT/Placebo OIT arm and 4 participants in the Active OIT/Placebo SLIT arm discontinued prior to month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Active SLIT/Placebo OIT</title>
            <description>These subjects will receive peanut powder given orally and placebo extract given sublingually.
Peanut powder: Delivered orally
Placebo extract: Delivered sublingually</description>
          </group>
          <group group_id="O2">
            <title>Active OIT/Placebo SLIT</title>
            <description>These subjects will receive peanut extract given sublingually and placebo powder given orally.
Peanut extract: Delivered sublingually
Placebo powder: Delivered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Between Arm Change in IgG4 From Baseline to 12 Months</title>
          <description>IgG4 levels are measured in milligrams of Antibody per liter (mga/L) and were collected at baseline and at 12 months</description>
          <population>One participant in the Active SLIT/Placebo OIT arm and 4 participants in the Active OIT/Placebo SLIT arm discontinued prior to month 12.</population>
          <units>mga/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.19" upper_limit="1.76"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.22" upper_limit="5.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="2.42" upper_limit="69.1"/>
                    <measurement group_id="O2" value="76" lower_limit="28.8" upper_limit="1790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Between Arm Change in IgE From Baseline to End of Dose Build-up (up to 16 Weeks)</title>
        <time_frame>Baseline to end of dose build-up (up to 16 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active SLIT/Placebo OIT</title>
            <description>These subjects will receive peanut powder given orally and placebo extract given sublingually.
Peanut powder: Delivered orally
Placebo extract: Delivered sublingually</description>
          </group>
          <group group_id="O2">
            <title>Active OIT/Placebo SLIT</title>
            <description>These subjects will receive peanut extract given sublingually and placebo powder given orally.
Peanut extract: Delivered sublingually
Placebo powder: Delivered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Between Arm Change in IgE From Baseline to End of Dose Build-up (up to 16 Weeks)</title>
          <units>kUa/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163" lower_limit="37.5" upper_limit="746"/>
                    <measurement group_id="O2" value="169" lower_limit="35.1" upper_limit="716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of dose build-up (up to 16 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="369" lower_limit="47.4" upper_limit="1960"/>
                    <measurement group_id="O2" value="392" lower_limit="84" upper_limit="1069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.40</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Between Arm Change in IgE From Baseline to 6 Months</title>
        <description>Serum immunoglobulin E (IgE) levels are measured in kilo units of Antibody per liter (kUa/L) and were collected at baseline and at 6 months</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active SLIT/Placebo OIT</title>
            <description>These subjects will receive peanut powder given orally and placebo extract given sublingually.
Peanut powder: Delivered orally
Placebo extract: Delivered sublingually</description>
          </group>
          <group group_id="O2">
            <title>Active OIT/Placebo SLIT</title>
            <description>These subjects will receive peanut extract given sublingually and placebo powder given orally.
Peanut extract: Delivered sublingually
Placebo powder: Delivered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Between Arm Change in IgE From Baseline to 6 Months</title>
          <description>Serum immunoglobulin E (IgE) levels are measured in kilo units of Antibody per liter (kUa/L) and were collected at baseline and at 6 months</description>
          <units>kUa/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163" lower_limit="37.5" upper_limit="746"/>
                    <measurement group_id="O2" value="169" lower_limit="35.1" upper_limit="716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="387" lower_limit="34.1" upper_limit="1032"/>
                    <measurement group_id="O2" value="68" lower_limit="50.9" upper_limit="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.07</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Between Arm Change in IgE From Baseline to 12 Months</title>
        <description>IgE levels are measured in kilo units of Antibody per liter (kUa/L) and were collected at baseline and at 12 months</description>
        <time_frame>Baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active SLIT/Placebo OIT</title>
            <description>These subjects will receive peanut powder given orally and placebo extract given sublingually.
Peanut powder: Delivered orally
Placebo extract: Delivered sublingually</description>
          </group>
          <group group_id="O2">
            <title>Active OIT/Placebo SLIT</title>
            <description>These subjects will receive peanut extract given sublingually and placebo powder given orally.
Peanut extract: Delivered sublingually
Placebo powder: Delivered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Between Arm Change in IgE From Baseline to 12 Months</title>
          <description>IgE levels are measured in kilo units of Antibody per liter (kUa/L) and were collected at baseline and at 12 months</description>
          <units>kUa/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163" lower_limit="37.5" upper_limit="746"/>
                    <measurement group_id="O2" value="169" lower_limit="35.1" upper_limit="716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273" lower_limit="21.0" upper_limit="1111"/>
                    <measurement group_id="O2" value="53" lower_limit="32.4" upper_limit="82.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.007</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Active SLIT/Placebo OIT</title>
          <description>Adverse event information is based on percentages of doses. There were 4578 total doses in the Active SLIT/Placebo OIT treatment arm</description>
        </group>
        <group group_id="E2">
          <title>Active OIT/Placebo SLIT</title>
          <description>Adverse event information is based on percentages of doses. There were 4049 total doses in the Active OIT/Placebo SLIT treatment arm</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4578"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4049"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4578"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4049"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="416" subjects_at_risk="4578"/>
                <counts group_id="E2" subjects_affected="1736" subjects_at_risk="4049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <description>including oral/pharyngeal symptoms</description>
                <counts group_id="E1" events="325" subjects_affected="325" subjects_at_risk="4578"/>
                <counts group_id="E2" events="1344" subjects_affected="1344" subjects_at_risk="4049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Symptoms</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="4578"/>
                <counts group_id="E2" events="279" subjects_affected="279" subjects_at_risk="4049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin symptoms</sub_title>
                <counts group_id="E1" events="64" subjects_affected="64" subjects_at_risk="4578"/>
                <counts group_id="E2" events="113" subjects_affected="113" subjects_at_risk="4049"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert A. Wood, MD</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-955-5883</phone>
      <email>rwood@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

